Shots:
- Jazz has entered into a preclinical research collaboration, option & license agreement with AbCellera to discover & develop next-generation T-cell engaging (TCE) multispecific antibodies for GI cancer & other solid tumors, leveraging AbCellera’s antibody discovery engine
- AbCellera will lead discovery & early-stage research for 2 initial programs, with a third to start within 12mos., while Jazz holds options for exclusive global development & commercialization rights. The companies may also add ~2 more programs, with AbCellera supporting IND-enabling studies & clinical supply manufacturing
- AbCellera will receive $56M upfront for the first 2 programs & $28M upon initiation of a third program, with potential option fees & milestone payments of ~$792M per program, plus tiered royalties ranging from mid-single to low double digits on net sales
Ref: Businesswire | Image: Jazz & AbCellera | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
